[Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature].
A 57-years old female patient with systemic sclerosis underwent a prolonged intravenous therapy during 21 consecutive days with iloprost, a stable analogue of prostacyclin. Beginning with 0.5 ng/ kg/minute the dose was increased every 2 days up to 2 ng/kg/minute. At the end of follow up, Iloprost was shown to enhance the perfusion of the finger and to improve pulmonary-function tests including the diffusion-capacity. Furthermore, the Erythrocyte Sedimentation Rate and the C-reactive protein decreased. The case report shows the necessity of a controlled study of prolonged iloprost therapy.
Riemekasten
G
G
Medizinische Univ.-Klinik und Poliklinik III, Universitätsklinikum Charité, Berlin.
Jepsen
H
H
Burmester
G R
GR
Hiepe
F
F
D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage*; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*
D014665:Vasodilator Agents; D016285:Iloprost
Iloprostgabe über 21 Tage als wirksame Therapie bei der progressiven systemischen Sklerodermie--Fallbeschreibung und Literaturübersicht.